Canada markets closed

BELLUS Health Inc. (BLU.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
12.14+0.29 (+2.45%)
At close: 04:00PM EDT
Sign in to post a message.
  • P
    Pete
    Wow !! All this without any news
  • j
    jirawut
    These go be like $SBFM Also canada stock.
  • S
    Sam
    What’s the news
  • D
    Duane
    You've got a Whale 🐋 on the Hook 🪝
  • M
    M
    The 3rd high close in the past few months. Once we close above 12.55; I charterdly see it in free float specially after the FDA nod to start P3.
  • J
    Jeff
    Moon
  • n
    nkov
    Any clues?
  • Y
    Yahoo Finance Insights
    BELLUS Health is up 7.57% to 8.81
  • Y
    Yahoo Finance Insights
    BELLUS Health is down 8.03% to 7.10
  • Y
    Yahoo Finance Insights
    BLU.TO is down 7.96% to 9.14
  • Y
    Yahoo Finance Insights
    BLU.TO is up 7.75% to 11.12
  • G
    Gabe
    BLU will most likely be bought within the the next few months. Crazy cheap market cap for the market potential
  • Y
    Yahoo Finance Insights
    BLU.TO is down 7.57% to 10.38
  • Y
    Yahoo Finance Insights
    BELLUS Health is down 7.72% to 7.70
  • Y
    Yahoo Finance Insights
    BELLUS Health is up 7.69% to 8.68
  • Y
    Yahoo Finance Insights
    BELLUS Health is down 7.72% to 8.13
  • J
    Josh
    SEC Form S-8 #$%$ filed by BELLUS Health Inc.
  • R
    Ram
    Huge bull call.. upgrade with target to $12... 400% upside that is the reason stock is moving up,,,

    https://seekingalpha.com/news/3637474-huge-bull-call-on-bellus-health-from-evercore-impliesplus-400-upside
    Stock Picks, Stock Market Investing
    seekingalpha.com
  • J
    J
    People always take profit when there is an announcement of Phase trials where the instant gratification is not there... BLU will continue to steadily climb. Those cashing in will regret it.
  • B
    Bildo
    From the Bellus web site: "second half of 2020"

    BELLUS Health believes BLU-5937 may be a viable treatment option for patients with chronic pruritus associated with atopic dermatitis. The Company has conducted preclinical studies of BLU-5937 in pruritus, and expects to initiate a Phase 2 trial to assess the efficacy, safety, and tolerability of BLU-5937 versus placebo in approximately 100 patients suffering from chronic pruritus associated with mild to moderate atopic dermatitis in the second half of 2020.